Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer

June 13, 2017

Join Eric Jonasch, MD and Marcia Holloway, APRN NP-C from The University of Texas MD Anderson Cancer Center as they present their expertise on a range of cases pertaining to kidney cancer.

Renal cell carcinoma (RCC) continues to have a significant health impact. In the United States, RCC is the sixth (6th) and eighth (8th) most common malignancy among men and women respectively, with 61,560 new cases and 14,080 deaths estimated in 2015.

Surgical resection remains the only effective therapy for clinically localized RCC. During the last three decades there have been steady improvements in surgical techniques and preoperative care, which have dramatically improved the ability to safely surgically resect tumors. Studies have demonstrated that oncologic outcomes are similar for patients undergoing partial or radical nephrectomy, particularly for patients with tumors confined to the kidney.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Determine optimal surgical approaches for patient with early-stage renal cell carcinoma.
  • Choose the optimal systemic therapy for advanced renal cell carcinoma using evidence-based data and patient characteristics.
  • Apply best practices to manage the adverse events associated with the new therapies available for advanced renal cell carcinoma.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas and Medivation, Inc, a Pfizer company; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
06/12/2017
Course expires: 
08/11/2017
Event starts: 
06/13/2017 - 11:00am
Event ends: 
06/13/2017 - 12:00pm
Cost:
$0.00

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center

Marcia Holloway, APRN, NP-C
The University of Texas MD Anderson Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below disclose no relevant financial relationships:
Marcia Holloway, APRN NP-C

The faculty listed below discloses the following relevant financial relationships:
Eric Jonasch, MD
Bristol-Myers Squibb Company: Consulting Fees, Honoraria
Eisai, Inc: Consulting Fees, Honoraria
Exelixis, Inc.: Consulting Fees, Honoraria, Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria, Grant/Research Support
Pfizer, Inc: Consulting Fees, Honoraria, Grant/Research Support
Roche Laboratories, Inc.: Consulting Fees, Honoraria

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/17); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/17)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Rashmi Kumar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. The course is approved for 1 CE contact hour. Activity Code: I00027277; Approval #: 170002285

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-071-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
06/12/2017
Course expires: 
08/11/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing